Rapid in vitro bromodeoxyuridine labeling method for monitoring of therapy response in solid human tumors.
In vitro bromodeoxyuridine (BrdUrd) incubated single-cell suspensions obtained from solid tumors were fixed on slides for subsequent sample processing. As dispersal of nuclei largely was avoided, only small amounts of cells were needed for examination. The sensitivity of detecting even low BrdUrd incorporation rates could be improved by treatment with intense DNA denaturation conditions. This technique was applied to monitor cytokinetic response to chemotherapy and radiation in oral carcinomas by analysing biopsies taken consecutively in the course of treatment. By combining BrdUrd labeling and DNA flow cytometry, cells arrested in S phase easily could be distinguished from cells showing continuous proliferation.
Hemmer
J
J
Department of Oral and Maxillofacial Surgery, University of Ulm, Federal Republic of Germany.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001973:Bromodeoxyuridine; D002277:Carcinoma / Q000032:analysis / Q000188:drug therapy* / Q000235:genetics; D002453:Cell Cycle; D002945:Cisplatin / Q000627:therapeutic use; D003114:Colony-Forming Units Assay; D004273:DNA, Neoplasm / Q000032:analysis*; D015251:Epirubicin / Q000627:therapeutic use; D005434:Flow Cytometry / Q000379:methods*; D006258:Head and Neck Neoplasms / Q000032:analysis / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D009062:Mouth Neoplasms / Q000032:analysis / Q000188:drug therapy* / Q000235:genetics; D014410:Tumor Stem Cell Assay
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D015251:Epirubicin; D001973:Bromodeoxyuridine; D002945:Cisplatin